Perfusion Systems Market Size, Share, Growth, Trends, and Global Industry Analysis: By type (Cardiopulmonary bypass, Extracorporeal Membrane Oxygenation, Isolated Limb Perfusion), By Device type (Hypothermic Machine Perfusion, Normothermic Machine Perfusion), By Application (Lungs, Heart, Liver, Kidneys), By End-User (Hospital, Specialty Clinics, Medical Research Centres, Academic Institutes) and Region Forecast 2020-2031

Perfusion Systems Market size was valued at US$ 1,368.1 million in 2024 and is expected to reach US$ 1,930.7 million by 2031, growing at a significant CAGR of 4.4% from 2025-2031. Moreover, the U.S. Perfusion Systems Market is projected to grow at 4.2% CAGR by 2031. The global market includes equipment and technologies that allow blood, oxygen, or other fluids to circulate through tissues, organs, or artificial systems during medical or surgical procedures. These systems are essential for organ transplants, cardiopulmonary bypass procedures, and cellular therapies. They include devices like as oxygenators, perfusion pumps, heart-lung machines, and ex vivo organ perfusion systems.

The market is expanding rapidly due to rising demand for organ transplantation, advances in medical technology, and an increase in the prevalence of cardiovascular and respiratory diseases. Innovations like normothermic machine perfusion for organ preservation are improving transplant results and generating market potential. North America has the largest market share due to its strong healthcare infrastructure, followed by Europe and the Asia-Pacific region, where increased investments in healthcare and rising awareness help to drive market growth. Collaborations between healthcare providers, research institutes, and device manufacturers to improve patient outcomes have also had an impact on the industry.

Facts & Figures

• Cardiopulmonary perfusion systems had the biggest market share in 2024 and are expected to grow the fastest. This growth is driven by the increasing number of cardiovascular diseases and operations, with 20.5 million cardiovascular-related deaths worldwide in 2021.?
• Japan's aging population, with over 10% of the population aged 80 or older by 2024, is a primary driver of the country's expanding demand for perfusion systems.?
• In the United States, the number of organ transplants increased by 5.9% in 2021, totalling 41,354 procedures, directly driving demand for perfusion systems.
• In February 2024, LivaNova introduced the Essenz perfusion system in Europe, a portable and flexible cardiopulmonary bypass system intended to improve cardiac surgery. This innovation reflects the current trends towards more adaptable and efficient perfusion systems.

List of Instances:

• In February 2024, LivaNova PLC, a medical technology company, announced the restricted commercial availability of their Essenz™ Perfusion System in selected European centers. This release comes after successful clinical trials at Catharina Hospital in Eindhoven, Netherlands, and San Donato Hospital in Milan, Italy. The Essenz system consists of a next-generation heart-lung machine (HLM) and an enhanced patient monitor that prioritizes data-driven decision-making during crucial cardiopulmonary bypass (CPB).
• In January 2024, Cleveland Clinic Florida initiated the Machine Perfusion Program for liver transplantation. This new technique employs modern machine perfusion technologies to increase liver preservation and viability during transit, increasing the success rate of liver transplants. By utilizing this technology, the clinic hopes to improve transplant patient outcomes while also expanding the donor liver pool.
• In August 2024, TransMedics Group, Inc., a medical technology firm that specializes in organ transplant therapy, has announced that it has acquired assets and intellectual property relating to Bridge to Life Ltd's Ex-Vivo Organ Support System (EVOSS) and LifeCradle Heart Preservation Transport System. EVOSS, which uses warm perfusion technology, is intended for lung and heart transplantation, whereas LifeCradle is a cold perfusion technique for heart transplants. TransMedics intends to further develop these technologies to broaden its organ transplant product line and applications.

Key Developments:

• In October 2024, Paragonix Technologies, a leader in organ transplant and procurement services, has been granted FDA 510(k) approval for its KidneyVault donor kidney preservation system. This is the company's first perfusion device, which combines portable hypothermic perfusion technology with enhanced digital monitoring to keep donor kidneys safe throughout transportation. The KidneyVault system intends to extend the donor pool by enhancing kidney preservation, representing a significant improvement in organ transplant technology.
• In October 2024, OrganOx Ltd., a leading business in organ medical technology, announced that Health Canada approved the OrganOx metra® System for use in liver transplantation. The device, which is presently available for liver transplantation in the United States, United Kingdom, and the European Union, is anticipated to be commercially available in Canada by 2025.
• In January 2024, Inspira Technologies OXY B.H.N Ltd., a leading life support technology company, announced the debut of a disposable blood oxygenation kit for their INSPIRA ART medical device series. Currently in development, the Kit is intended to be interoperable with a variety of life support machines, allowing it to enter the burgeoning disposable market. This new solution seeks to revolutionize life support technology by offering an alternative to standard mechanical ventilators.

Perfusion Systems Market Segmentation:

Based on the type:

• Cardiopulmonary bypass
• Extracorporeal Membrane Oxygenation
• Isolated Limb Perfusion

Cardiopulmonary bypass (CPB) systems lead the market, owing to their widespread use in open-heart surgery and other important cardiovascular procedures. The rising prevalence of cardiovascular ailments, such as coronary artery disease and heart valve abnormalities, is driving demand for CPB systems. According to the World Health Organization, cardiovascular illnesses are the main cause of death worldwide, accounting for nearly 17.9 million deaths per year, highlighting the need for better surgical procedures. 

CPB systems perform an important role in sustaining blood circulation and oxygenation during procedures that require the heart to be temporarily stopped, assuring patient safety and procedural effectiveness. Technological developments, such as smaller systems with improved safety features, are accelerating their implementation. Furthermore, as the number of cardiac centres grows and healthcare services become more accessible in emerging nations, the utilization of CPB systems is increasing. The incorporation of real-time monitoring and AI-driven diagnostics into CPB devices improves their functionality and contributes to better surgical results. These characteristics combine to solidify cardiopulmonary bypass systems as the main section of the market, catering to both routine and difficult cardiovascular surgery needs.

Based on the Device type:

• Hypothermic Machine Perfusion
• Normothermic Machine Perfusion

Normothermic machine perfusion (NMP) is developing as the leading sector in the market due to its increased capacity to keep organs in a healthy state during preservation and transplantation procedures. Unlike hypothermic machine perfusion, which uses frigid temperatures to inhibit metabolic activity, NMP keeps the organ at normal body temperature, allowing it to function and receive oxygen, nutrition, and needed drugs. This method has been shown to increase organ viability and permit longer preservation timeframes, particularly for marginal or high-risk donor organs. 

The capacity to analyse organ function in real time prior to transplantation is a key driver of NMP's leadership. This trait is very important for minimizing the risk of organ rejection and increasing transplant success rates. Studies have indicated that organs preserved using NMP, such as livers and kidneys, have higher post-transplant survival rates and longer-term outcomes. Furthermore, the increased prevalence of organ failure drives up the demand for organ transplants, hastening the deployment of NMP systems. 

Based on the Application:

• Lungs
• Heart
• Liver
• Kidneys

Kidneys are the prevailing application category in the market, owing to the high prevalence of chronic kidney disease (CKD) and the global need for kidney transplants. According to the International Society of Nephrology, CKD affects over 10% of the global population, with millions requiring renal replacement therapy or transplantation each year. This has made kidney transplants one of the most popular and important procedures, with perfusion systems key to organ preservation and viability. Perfusion methods for kidneys, particularly hypothermic and normothermic machine perfusion, have proven effective in minimizing ischemia-reperfusion harm, prolonging organ preservation durations, and improving post-transplant outcomes.

These systems improve oxygenation and food supply during storage, keeping the organ functional and healthy for transplantation. The increased availability of expanded criteria and marginal kidneys has highlighted the need for better perfusion procedures, as these organs require thorough preservation and evaluation prior to transplantation.

Based on the end user:

• Hospital
• Specialty Clinics
• Medical Research Centres
• Academic Institutes

Hospitals are the largest end-user category in the market, owing to their vital involvement in organ transplantation and high-volume surgical procedures that necessitate sophisticated perfusion support. Hospitals, particularly those with specialized transplant facilities, are the principal places where life-saving surgeries like heart, kidney, liver, and lung transplants are performed. According to the Global Observatory on Donation and Transplantation (GODT), hospitals execute most organ transplant surgeries worldwide, making them the primary users of perfusion systems.

The rising occurrence of organ failure, particularly among the elderly, fuels the demand for perfusion systems in hospitals. With an increasing number of transplant surgeries conducted annually, hospitals rely largely on sophisticated perfusion technologies to assure the viability of donor organs after transplantation. Furthermore, advances in perfusion system technology, such as real-time monitoring, artificial intelligence, and improved preservation techniques, have increased transplant efficiency and results. These improvements assist hospitals by increasing success rates while reducing complications associated with organ rejection and post-operative rehabilitation.